Genmab A/s
A Danish biotechnology company that designs antibody-based medicines to treat cancer and other serious diseases. Its best-known drug is Darzalex, a treatment for the blood cancer multiple myeloma that it co-developed with Johnson & Johnson's Janssen division. Founded in 1999 in Copenhagen by two researchers, it takes its name from a blend of "gen" for genetics and "mab," the standard abbreviation for monoclonal antibody—the very molecules it engineers.
Sponsored ADR
No insider transactions reported in the last year. Look across all recorded history →